PALO ALTO: Inceptive, a pioneering startup dedicated to harnessing the power of artificial intelligence for the development of innovative drugs and vaccines, has successfully secured a substantial $100 million in funding.

Co-founded by former Google AI researcher Jakob Uszkoreit, a trailblazer in Google’s generative AI efforts, Inceptive is headquartered in Palo Alto.

The company’s mission centers around the creation of cutting-edge software tools designed for the purpose of “rationally designing groundbreaking, widely accessible medications and biotechnologies that were previously beyond our grasp.” Inceptive’s primary emphasis lies in advancing RNA-based medicines.

This $100 million funding round, following a previous seed funding injection of $20 million last year, has garnered support from prominent backers, including Nvidia, Andreessen Horowitz, and Obvious Ventures. The substantial capital infusion will enable Inceptive to expand and enhance the capabilities of its innovative platform.

Inceptive’s ambitious pursuit of leveraging artificial intelligence to revolutionize the realm of drug and vaccine design promises to drive significant advancements in the field of medicine and biotechnology, ultimately benefiting humanity as a whole.

SaaSGrid secures $3.3 million in seed funding led by Craft Ventures